PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
88.67%
Positive growth while VET shows revenue decline. John Neff would investigate competitive advantages.
1.04%
Cost increase while VET reduces costs. John Neff would investigate competitive disadvantage.
189.76%
Positive growth while VET shows decline. John Neff would investigate competitive advantages.
53.58%
Margin expansion while VET shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-24.18%
G&A reduction while VET shows 16.80% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Other expenses reduction while VET shows 373.08% growth. Joel Greenblatt would examine efficiency.
-26.34%
Operating expenses reduction while VET shows 14.81% growth. Joel Greenblatt would examine advantage.
-10.15%
Total costs reduction while VET shows 5.40% growth. Joel Greenblatt would examine advantage.
-6.52%
Interest expense reduction while VET shows 5.34% growth. Joel Greenblatt would examine advantage.
-0.29%
D&A reduction while VET shows 4.86% growth. Joel Greenblatt would examine efficiency.
259.24%
EBITDA growth exceeding 1.5x VET's 45.02%. David Dodd would verify competitive advantages.
111.54%
EBITDA margin growth while VET declines. John Neff would investigate advantages.
1037.82%
Operating income growth while VET declines. John Neff would investigate advantages.
503.08%
Operating margin growth while VET declines. John Neff would investigate advantages.
-136.49%
Other expenses reduction while VET shows 302.19% growth. Joel Greenblatt would examine advantage.
2520.00%
Similar pre-tax income growth to VET's 2458.26%. Walter Schloss would investigate industry trends.
1288.68%
Pre-tax margin growth below 50% of VET's 2723.91%. Michael Burry would check for structural issues.
2383.33%
Tax expense growth 50-75% of VET's 4547.80%. Bruce Berkowitz would examine efficiency.
2541.03%
Net income growth 1.25-1.5x VET's 2241.68%. Bruce Berkowitz would examine sustainability.
1299.82%
Net margin growth 50-75% of VET's 2482.94%. Martin Whitman would scrutinize operations.
2595.00%
EPS growth 1.25-1.5x VET's 2210.00%. Bruce Berkowitz would examine sustainability.
2595.00%
Diluted EPS growth 1.25-1.5x VET's 2208.98%. Bruce Berkowitz would examine sustainability.
-0.18%
Share count reduction while VET shows 1.27% change. Joel Greenblatt would examine strategy.
No Data
No Data available this quarter, please select a different quarter.